@article{TLCR27712,
author = {Keisuke Onoi and Yoshiko Kaneko and Junji Uchino},
title = {Osimertinib in first line setting: for Asian patients},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {4},
year = {2019},
keywords = {},
abstract = {The discovery of the epidermal growth factor receptor (EGFR) gene as the first driver gene in lung cancer has led to a major paradigm shift in lung cancer treatment. Gefitinib and other EGFR-tyrosine kinase inhibitors (TKIs) have demonstrated excellent antitumor activity against EGFR mutation-positive non-small cell lung cancer (NSCLC). However, resistance to TKI emerged over the course of treatment, and resistance due to T790M mutations was noted in approximately half of the cases (1,2).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/27712}
}